Drug regulators skeptical about Chinese firm's COVID-19 drug



The stock price of Chinese biotech firm Kintor Pharmaceutical Limited jumped by more than 20% the day after it announced the 'completion of the first patient enrollment and dosing' in a late-stage U.S. clinical trial of its experimental COVID-19 treatment.